Can new chemical therapies improve the management of multiple sclerosis in children?

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2002 Apr 6;359(9313):1221–1231.
   PubMed Web of Science ®Google Scholar
• Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2009 Jun;22(3):233–240.
   PubMed Web of Science ®Google Scholar
• Ruggieri M, Iannetti P, Polizzi A, et al. Multiple sclerosis in children under 10 years of age. Neurological Sci. 2004;25(4): S326–S335.
   Google Scholar
• Krupp LB, Banwell B, Tenembaum S. International pediatric MS study group, consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurol. 2007;68(16):S7–S12. supplement 2.
   Google Scholar
• Krupp LB, Tardieu M, Amato MP, et al. international pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J. 2013;19(10):1261–1267.
   PubMed Web of Science ®Google Scholar
• Sadaka Y, Verhey LH, Shroff MM, et al. 2010McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012;72(2):211–223.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Chabas D, Castillo-Trivino T, Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 2008 Sep 30;71(14):1090–1093.
   PubMed Web of Science ®Google Scholar
• Hahn JS, Pohl D, Rensel M, et al. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology. 2007;68(16):S13–S22. supplement 2.
   Google Scholar
• Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012;27(11):1378–1383.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Absinta M, Ghezzi A, et al. Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients? Hum Brain Mapp. 2009 Sep;30(9):2844–2851.
   PubMed Web of Science ®Google Scholar
• Mar S, Lenox J, Benzinger T, et al. Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis. J Child Neurol. 2010;25(6):681–688.
   PubMed Web of Science ®Google Scholar
• Wassmer E, Chitnis T, Pohl D, et al. International pediatric MS study group global members symposium report. Neurology. 2016;87(Suppl 2):S110–S116.
   Google Scholar
• Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2:295–301.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm. 2015;2:e81.
   PubMedGoogle Scholar
• Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler. 2015;21:1513–1520.
   PubMed Web of Science ®Google Scholar
• Callen DJA, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009;72(11):968–973.
   PubMed Web of Science ®Google Scholar
• Chabas D, Green AJ, Waubant E. Pediatric multiple sclerosis. NeuroRx. 2006 Apr;3(2):264–275.
   PubMedGoogle Scholar
• Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2007;6(10):887–902.
   PubMed Web of Science ®Google Scholar
• Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66:54.
   PubMed Web of Science ®Google Scholar
• Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014 Mar;3(2):186–193.
   PubMed Web of Science ®Google Scholar
• Tenembaum SN. Therapy of multiple sclerosis in children and adolescents. Clin Neurol Neurosurg. 2010 Sep;112(7):633–640.
   PubMed Web of Science ®Google Scholar
• Trojano M, Paolicelli D, Bellacosa A, et al. Atypical forms of multiple sclerosis or different phases of a same disease? Neurol Sci. 2004;25(Suppl 4):Ss323–s325.
   Google Scholar
• Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005;64:891–894.
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70:1891–1897.
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010;75:1134–1140.
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014 Oct 14;83(16):1432–1438.
   PubMed Web of Science ®Google Scholar
• Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2004;4:245.
   PubMedGoogle Scholar
• D’Amico E, Leone C, Caserta C, et al. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother. 2015;15(7):803–824.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Messina S, Caserta C, et al. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opin Drug Saf. 2015 Jul;14(7):1157–1168.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Caserta C, Patti F. Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Rev Neurother. 2015 Mar;15(3):251–268.
   PubMed Web of Science ®Google Scholar
• Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011;26:675.
   PubMed Web of Science ®Google Scholar
• Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56(11):1219–1220.
   PubMed Web of Science ®Google Scholar
• Burton JM, O’Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006921.
   Google Scholar
• Waldman A, Gorman M, Rensel M, et al. Pediatric CNS demyelinating disorders: survey of US practice patterns. J Child Neurol. 2011 Jun;26(6):675–682.
   PubMed Web of Science ®Google Scholar
• Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381–389.
   PubMed Web of Science ®Google Scholar
• Berkovich R, Fernandez M, Subhani D Adrenocorticotropic hormone treatment of multiple sclerosis exacerbations. Presented at the Consortium of Multiple Sclerosis Centers; June 2, 2012; San Diego.
   Google Scholar
• Cortese V, Chaudhry YT, So F, et al. Evidence-based guideline update: plasmapheresis in neurologis disorders: report of the therapeutics and technology assessment subcommittee of the Americal Academy of Neurology. Neurology. 2011;76:294–300.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosupression for acute attacks of multiple sclerosis.. Neurology. 1989;38:1143–1149.
   Google Scholar
• Schilling S, Linker RA, Konig FB, et al. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt. 2006;77(4):430–438.
   PubMed Web of Science ®Google Scholar
• Takahashi I, Sawaishi Y, Takeda O, et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol. 1997;17(1):83–88.
   PubMed Web of Science ®Google Scholar
• Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler (Houndmills, Basingstoke, England). 2004;10(1):89–91.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63(11):2028–2033.
   PubMed Web of Science ®Google Scholar
• Sahlas DJ, Miller SP, Guerin M, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54:1370–1372.
   PubMed Web of Science ®Google Scholar
• Andersson UG, Bjork L, Skansen-Saphir U, et al. Downregulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology. 1993;79:211–216.
   PubMed Web of Science ®Google Scholar
• Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev. 1989;110:135–149.
   PubMed Web of Science ®Google Scholar
• Straussberg R, Schonfeld T, Weitz R, et al. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol. 2001;24(2):139–143.
   PubMed Web of Science ®Google Scholar
• Spalice A, Properzi E, Lo Faro V, et al. Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis. J Child Neurol. 2004;19(8):623–626.
   PubMed Web of Science ®Google Scholar
• Shahar E, Andraus J, Savitzki D, et al. Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol. 2002;17(11):810–814.
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993 Apr;43(4):655–661.
   PubMed Web of Science ®Google Scholar
• Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–294.
   PubMed Web of Science ®Google Scholar
• Tenembaum SN, Segura MJ. Interferon β-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511–513.
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-β treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139(3):443–446.
   PubMed Web of Science ®Google Scholar
• Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon β-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472–476.
   PubMed Web of Science ®Google Scholar
• Pohl D, Rostasy K, Gartner J, et al. Treatment of early onset multiple sclerosis with subcutaneous interferon β-1a. Neurology. 2005;64(5):888–890.
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005 Nov;12(11):817–827.
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 Jul;9(7):740–750. DOI:10.1016/S1474-4422(10)70103-4.
   PubMed Web of Science ®Google Scholar
• Hunt D, Kavanagh D, Drummond I. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014 Mar 27;370(13):1270–1271. DOI:10.1056/NEJMc1316118.
   PubMed Web of Science ®Google Scholar
• Capobianco M, Piccoli G, Neve Vigotti F, et al. Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. Mult Scler. 2014 Jun;20(7):889–891. Epub 2014 Jan 20 DOI:10.1177/1352458513519839.
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002;201:71–77.
   PubMed Web of Science ®Google Scholar
• Narula S, Banwell B. Treatment of multiple sclerosis in children and its challenges. Presse Med. 2015 Apr;44(4 Pt 2):e153–8.
   PubMedGoogle Scholar
• Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116.
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11:420.
   PubMed Web of Science ®Google Scholar
• Yeh EA, Waubant E, Krupp LB, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011;68:437–444.
   PubMedGoogle Scholar
• Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 Jan;66(1):54–59. DOI:10.1001/archneurol.2008.505.
   PubMed Web of Science ®Google Scholar
• Yeh EA, Weinstock-Guttman B, Ramanathan M, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3392–3400. DOI:10.1093/brain/awp278.
   PubMed Web of Science ®Google Scholar
• Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007 Jun 21;356(25):2603–2613.
   PubMed Web of Science ®Google Scholar
• Yeh A. Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies. Adolesc Health Med Ther. 2010;1:61–71.
   PubMedGoogle Scholar
• Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63(12 Suppl 6):S33–S40.
   Google Scholar
• Huppke P, Stark W, Zurcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65:1655–1658.
   PubMed Web of Science ®Google Scholar
• Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259–268.
   PubMedGoogle Scholar
• Ghezzi A, Moiola L, Pozzilli C, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015 Sep;25(15):174.
   Web of Science ®Google Scholar
• Kornek B, Aboul-Enein F, Rostasy K, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013 Apr;70(4):469–475. DOI:10.1001/jamaneurol.2013.923..
   PubMed Web of Science ®Google Scholar
• Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010 Sep;3(5):293–299.
   PubMedGoogle Scholar
• Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015 Jul;29(7):565–575.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011 Aug;25(8):673–698.
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Alves-Leon SV, Barreira AA, et al. Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years. Pediatr Neurol. 2015 Aug;53(2):166–168.
   PubMed Web of Science ®Google Scholar
• Gärtner, Chitnis T, Banwell B, et al. PARADIGMS: Fingolimod in children and adolescents with MS. J. Neuropediatrics. 2014;45:p026. DOI:10.1055/s-0034-1390598
   Google Scholar
• Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler (Houndmills, Basingstoke, England). 2009;15(11):1303–1310.).
   Google Scholar
• Chitnis T, Glanz B, Jaffin S, et al. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler (Houndmills, Basingstoke, England). 2009;15(5):627–631.
   PubMed Web of Science ®Google Scholar
• Yeh E, Krupp L, Ness J, et al. Breakthrough disease in pediatric MS patients: a pediatric network experience. Annual Meeting of the American Academy of Neurology; 2009, Seattle, WA.
   Google Scholar
• Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72:2076.
   PubMed Web of Science ®Google Scholar
• Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016 Jul;15(7):714–718.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31–45. DOI:10.1177/1756285614563522
   PubMed Web of Science ®Google Scholar
• LEMTRADA [prescribing information]. Cambridge, MA: Genzyme Corporation; 2016. [cited 2016 Nov]. Available from: www.lemtradahcp.com
   Google Scholar
• Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9(1):44–52. DOI:10.1177/1756285615601933
   PubMed Web of Science ®Google Scholar
• A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis. [cited 2016 Nov]. Available from: http://clinicaltrials.gov/ct2/show/NCT01247324.
   Google Scholar
• A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis. [cited 2016 Nov]. Available from: http://clinicaltrials.gov/ct2/show/NCT01412333.
   Google Scholar
• A Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis. [cited 2016 Nov]. Available from: http://clinicaltrials.gov/ct2/show/NCT01194570.
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400.
   PubMed Web of Science ®Google Scholar
• Karenfort M, Kieseier BC, Tibussek D, et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol. 2009;51(2):159–161.
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Herman M, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology. 2011;77:1877–1886.
   PubMed Web of Science ®Google Scholar
• Huss D, Mehta D, You X, et al. IL-2Rßy-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients [abstract P950]. Mult Scler J. 2014;20(Suppl. 1):482.
   Google Scholar
• Kappos L, Selmaj K, Arnold D et al. (2015) Daclizumab HYP versus interferon beta-1a in relapsing-remitting multiple sclerosis: primary results of the DECIDE study [abstract S4.003]. Presented at the 67th Annual Meeting of the American Academy of Neurology, 18–25 April 2015, Washington DC.
   Google Scholar
• Selmaj K, Kappos L, Arnold D et al. (2014) Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study [poster]. Presented at the Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, 10–13 September 2014, Boston, MA.
   Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014 Apr;74(6):659–674.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi L, et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. J Neurol. 2012;259(Suppl. 1):1–236.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Oh J, O’Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2014 Sep;7(5):239–252.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky J, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Tortorella C, Gasperini C. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2014 Mar 27;10:229–239.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Define study investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Confirm study investigators Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Alvarez-Gonzalez C, Allen-Philbey K, Mathews J. et al. Treating multiple sclerosis with generic cladribine. ECTRIMS Online Library. Sep 16, 2016; 145845.
   Google Scholar
• Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology. 2008 Jan;123(1):66–78. Epub 2007 Oct 16.
   PubMed Web of Science ®Google Scholar
• Simone M, Chitnis T. Use of disease-modifying therapies in pediatric MS. Curr Treat Options Neurol. 2016 Aug;18(8):36. DOI:10.1007/s11940-016-0420-7.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Leone C, Zanghì A, et al. Lateral and escalation therapy in relapsing- remitting multiple sclerosis: a comparative study. J Neurol. 2016 Sep;263(9):1802–1809.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use and Pediatric Committee (2013) Guideline on the pharmaceutical development of medicines for pediatric use (adopted). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf
   Google Scholar
• Courant F, Aksglaede L, Antignac JP, et al. Assessment of circulating sex steroid levels in prepubertal and pubertal boys and girls by a novel ultrasensitive gas chromatography-tandem mass spectrometry method. J Clin Endocrinol Metab. 2010 Jan;95(1):82–92.
   PubMed Web of Science ®Google Scholar
• Schultz C, Reiss I, Bucsky P, et al. Maturational changes of lymphocyte surface antigens in human blood: comparison between fetuses, neonates and adults. Biol Neonate. 2000;78(2):77–82.
   PubMedGoogle Scholar
• Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419–428.
   PubMedGoogle Scholar
• Gui J, Mustachio LM, Su DM, et al. Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors andStroma. Aging Dis. 2012 Jun;3(3):280–290.
   PubMed Web of Science ®Google Scholar
• Yager EJ, Ahmed M, Lanzer K, et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity toinfluenza virus. J Exp Med. 2008 Mar 17;205(3):711–723.
   PubMed Web of Science ®Google Scholar
• Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood. 2000 May 1;95(9):2860–2868.
   PubMed Web of Science ®Google Scholar